Epilepsy in Nicolaides–Baraitser Syndrome: Review of Literature and Report of 25 Patients Focusing on Treatment AspectsFunding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Nicolaides–Baraitser syndrome (NCBRS), caused by a mutation in the SMARCA2 gene, which goes along with intellectual disability, congenital malformations, especially of face and limbs, and often difficult-to-treat epilepsy, is surveyed focusing on epilepsy and its treatment. Patients were recruited via “Network Therapy of Rare Epilepsies (NETRE)” and an international NCBRS parent support group. Inclusion criterion is NCBRS-defining SMARCA2 mutation. Clinical findings including epilepsy classification, anticonvulsive treatment, electroencephalogram (EEG) findings, and neurodevelopmental outcome were collected with an electronic questionnaire. Inclusion of 25 NCBRS patients with epilepsy in 23 of 25. Overall, 85% of the participants (17/20) reported generalized seizures, the semiology varied widely. EEG showed generalized epileptogenic abnormalities in 53% (9/17), cranial magnetic resonance imaging (cMRI) was mainly inconspicuous. The five most frequently used anticonvulsive drugs were valproic acid (VPA [12/20]), levetiracetam (LEV [12/20]), phenobarbital (PB [8/20]), topiramate (TPM [5/20]), and carbamazepine (CBZ [5/20]). LEV (9/12), PB (6/8), TPM (4/5), and VPA (9/12) reduced the seizures' frequency in more than 50%. Temporary freedom of seizures (>6 months) was reached with LEV (4/12), PB (3/8), TPM (1/5, only combined with PB and nitrazepam [NZP]), and VPA (4/12). Seizures aggravation was observed under lamotrigine (LTG [2/4]), LEV (1/12), PB (1/8), and VPA (1/12). Ketogenic diet (KD) and vagal nerve stimulation (VNS) reduced seizures' frequency in one of two each. This first worldwide retrospective analysis of anticonvulsive therapy in NCBRS helps to treat epilepsy in NCBRS that mostly shows only initial response to anticonvulsive therapy, especially with LEV and VPA, but very rarely shows complete freedom of seizures in this, rather genetic than structural epilepsy.
We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
Received: 16 July 2020
Accepted: 10 December 2020
12 February 2021 (online)
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Hofmeister B, von Stülpnagel C, Berweck S, Abicht A, Kluger G, Weber P. Cooccurrence of two different genetic diseases: a case of valproic acid hepatotoxicity in nicolaides-baraitser syndrome (SMARCA2 mutation)-due to a POLG1-related effect?. Neuropediatrics 2020; 51 (01) 49-52
- 2 Van Houdt JK, Nowakowska BA, Sousa SB. et al. Heterozygous missense mutations in SMARCA2 cause Nicolaides-Baraitser syndrome. Nat Genet 2012; 44 (04) 445-449 , S1
- 3 Hargreaves DC, Crabtree GR. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res 2011; 21 (03) 396-420
- 4 Wang W, Côté J, Xue Y. et al. Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J 1996; 15 (19) 5370-5382
- 5 Phelan ML, Sif S, Narlikar GJ, Kingston RE. Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. Mol Cell 1999; 3 (02) 247-253
- 6 Chi TH, Wan M, Zhao K. et al. Reciprocal regulation of CD4/CD8 expression by SWI/SNF-like BAF complexes. Nature 2002; 418 (6894): 195-199
- 7 Yoo AS, Staahl BT, Chen L, Crabtree GR. MicroRNA-mediated switching of chromatin-remodelling complexes in neural development. Nature 2009; 460 (7255): 642-646
- 8 Lessard J, Wu JI, Ranish JA. et al. An essential switch in subunit composition of a chromatin remodeling complex during neural development. Neuron 2007; 55 (02) 201-215
- 9 Reyes JC, Barra J, Muchardt C, Camus A, Babinet C, Yaniv M. Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha). EMBO J 1998; 17 (23) 6979-6991
- 10 Cohen-Armon M, Visochek L, Katzoff A. et al. Long-term memory requires polyADP-ribosylation. Science 2004; 304 (5678): 1820-1822
- 11 Vogel-Ciernia A, Matheos DP, Barrett RM. et al. The neuron-specific chromatin regulatory subunit BAF53b is necessary for synaptic plasticity and memory. Nat Neurosci 2013; 16 (05) 552-561
- 12 Butler LS, Silva AJ, Abeliovich A, Watanabe Y, Tonegawa S, McNamara JO. Limbic epilepsy in transgenic mice carrying a Ca2+/calmodulin-dependent kinase II alpha-subunit mutation. Proc Natl Acad Sci U S A 1995; 92 (15) 6852-6855
- 13 Sousa SB, Hennekam RC. Nicolaides-Baraitser Syndrome International Consortium. Phenotype and genotype in Nicolaides-Baraitser syndrome. Am J Med Genet C Semin Med Genet 2014; 166C (03) 302-314
- 14 Mari F, Marozza A, Mencarelli MA. et al. Coffin-Siris and Nicolaides-Baraitser syndromes are a common well recognizable cause of intellectual disability. Brain Dev 2015; 37 (05) 527-536
- 15 Tang S, Hughes E, Lascelles K, Simpson MA, Pal DK. EuroEPINOMICS RES myoclonic astatic epilepsy working group. New SMARCA2 mutation in a patient with Nicolaides-Baraitser syndrome and myoclonic astatic epilepsy. Am J Med Genet A 2017; 173 (01) 195-199
- 16 Al-Tamimi B, Abela S, Jeremiah HG, Evans RD. Supernumeraries in Nicolaides-Baraitser syndrome. Int J Paediatr Dent 2017; 27 (06) 583-587
- 17 Sethi S, Thau A, Kaplan P, Asher SB, Levin AV. Glaucoma and degenerative vitreoretinopathy in a girl with Nicolaides-Baraitser syndrome. J AAPOS 2019; 23 (03) 169-171
- 18 Hoyer J, Ekici AB, Endele S. et al. Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disability. Am J Hum Genet 2012; 90 (03) 565-572
- 19 Cramer JA, Arrigo C, Van Hammée G, Gauer LJ, Cereghino JJ. Effect of levetiracetam on epilepsy-related quality of life. N132 study group. Epilepsia 2000; 41 (07) 868-874
- 20 Isojärvi JI, Taubøll E, Herzog AG. Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs 2005; 19 (03) 207-223
- 21 de Silva M, MacArdle B, McGowan M. et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347 (9003): 709-713
- 22 Wallace H, Shorvon SD, Hopkins A, O'Donoghue M. Adults with Poorly Controlled Epilepsy: Guidelines for Treatment. London, United Kingdom: Royal College of Physicians; 1997
- 23 Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disorder 2011; 4 (06) 385-407